Fundraising FoxArrive — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Samsara BioCapital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.